To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
NCT05852431 · ENTRUST Phase 3Completed
- Lead sponsor
- 89bio, Inc. (Industry)
- Enrollment
- 369 (actual)
- Start date
- 15 Jun 2023
- Primary completion
- 7 Jul 2025 (actual)
- Study completion
- 9 Apr 2026
- Last update posted
- 7 Jul 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 3
Interventions
- Pegozafermin Drug
- Placebo Drug
Conditions and primary outcome
- Severe Hypertriglyceridemia
Primary outcome
Percent change from baseline in fasting TG (26 weeks)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05852431.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05852431 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.